2024 World Conference on Lung Cancer (WCLC) - Posters-P3.12C.03 Efficacy and Safety of Brigimadlin, a MDM2-p53 Antagonist, in Patients with Advanced Lung Adenocarcinoma

P3.12C.03 Efficacy and Safety of Brigimadlin, a MDM2-p53 Antagonist, in Patients with Advanced Lung Adenocarcinoma

Pdf Summary

The study focuses on brigimadlin, an MDM2–p53 antagonist, and its efficacy and safety in patients with advanced lung adenocarcinoma (LUAD). Brigimadlin was compared in monotherapy and combination therapy settings. The study observed that brigimadlin could potentially extend the treatment duration beyond what previous regimens provided, indicating its promising role for patients typically having a poor prognosis due to MDM2 amplification (MDM2-amp).<br /><br />Patient data was collected from several international trials. In monotherapy among 12 evaluable patients, 4 achieved partial response (PR), 2 had an unconfirmed PR, and 5 had stable disease (SD). In combination therapy, out of 8 evaluable patients, 1 had a PR, 1 an unconfirmed PR, and 5 achieved SD. Safety analysis indicated that neutropenia and decreased platelet count were common, serious adverse events, but no treatment discontinuations were recorded due to adverse effects.<br /><br />The study demonstrates brigimadlin's potential efficacy in patients with LUAD, particularly where MDM2 amplification indicates a poor prognosis. Genetic profiling of patients revealed complex genomic alterations, including co-amplifications and mutations with MDM2, EGFR, and CDK4 genes being prominent.<br /><br />Overall, the results are supportive of the continued investigation of brigimadlin in LUAD treatment, offering potential benefits for patients who have previously discontinued other therapies relatively quickly due to lack of efficacy or adverse effects. The promising preliminary efficacy, marked by durable responses and stable disease in patients unresponsive to prior treatments, highlights brigimadlin's potential as a therapeutic option for LUAD, particularly in cases involving MDM2 gene amplification.

Asset Subtitle

Noboru Yamamoto

Meta Tag

Speaker Noboru Yamamoto

Topic Metastatic NSCLC – Targeted Therapy

Keywords

brigimadlin

MDM2–p53 antagonist

lung adenocarcinoma

monotherapy

combination therapy

MDM2 amplification

neutropenia

genomic alterations

EGFR

CDK4